Melanoma Global Clinical Trials Review, H1, 2016 The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023, representing a robust Compound Annual Growth Rate (CAGR) of 15.5%, according to MarketIntelReports Published on – 31,January, 2016 | Number of pages :NA Single User Price: $2500
“Melanoma Global Clinical Trials Review, H1, 2016" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. MarketIntelReports latest report states that this impressive growth, which will occur across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK, Japan, and Australia, will be driven primarily by increasing sales of Bristol-Myers Squibb's blockbuster immunotherapy Yervoy. "While Yervoy's sales will be negatively impacted by the first-line uptake of PD-1targeting monoclonal antibodies (mAbs) Keytruda and Opdivo from 2015 to 2017, the approval of the Yervoy/Opdivo combination will recover the former's market position in the second half of the forecast period. "Furthermore, Yervoy's label expansion into the lucrative adjuvant setting will further enhance its sales from 2019 onwards."
Some of the prominent players of market: Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Merck & Co., Inc. Novartis AG AstraZeneca Plc Pfizer Inc. Ludwig Institute For Cancer Research Ltd Eisai Co., Ltd. Amgen Inc. and Others The BRAF/MEK inhibitor combinations, in particular Novartis' Tafinlar/Mekinist and Roche/Exelixis' Zelboraf/cobimetinib, will replace standard BRAF inhibitor monotherapy of Zelboraf or Tafinlar. In addition, Keytruda and Opdivo will garner rapid growth in both BRAF mutated and wild-type settings. "These novel agents and combinations will experience large uptake globally, thanks to their improved overall response rate and overall survival, along with their manageable side effect profiles. Notably, the combination treatments will fetch a higher premium price than monotherapies, which, on top of raising company sales, will also result in greater pushback from payers."
Click Here To Check Complete Report
MarketIntelReports expects these new, more efficacious entrants to replace generic chemotherapy-only regimens in the first- and second-line settings, therefore driving the growth of the overall melanoma market and extending the lines of treatment available for patients. "The launch of these improved agents will ensure that many patients receive one to two lines of treatment with branded premium-priced drugs by 2023 and beyond."
Download Sample Brochure
Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Make an Inquiry Before Buying
Melanoma Global Clinical Trials Review, H1, 2016 A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Melanoma Global Clinical Trials Review, H1, 2016 and future opportunities are provided in the report.
Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com
Click Here To Order Melanoma Global Clinical Trials Review, H1, 2016 Market Report